Berberine's lipid-lowering effect on human body is well-known. The researchers confirmed it through a meta-analysis of 27 clinical studies involving 2569 participants. Compared with the meta-analysis, the results show that increasing silymarin (berberine) can have a positive impact on human lipid and glucose metabolism, allowing the use of lower doses (berberine), thereby reducing the risk of dose-related gastrointestinal discomfort.
Italian scientists conducted a systematic review of the literature and found that five RCTs were included in their meta-analysis. The data came from 497 people. The duration of the study ranged from 3 to 12 months, with berberine at 500 or 1000 mg / day and silymarin at 105 or 210 mg / day.
The results showed that the total cholesterol, triglyceride, LDL cholesterol and HDL cholesterol decreased by 25 mg / dl, 28 mg / dl, 29 mg / dl and 6 mg / dl respectively. Existing studies have shown that berberine combined with silymarin can improve blood lipid and blood glucose levels, which may be used to promote cardiac metabolic health.
